Target intelligence / Profile preview

Cadherin-23 (CDH23)

Target
CDH23
Molecular classification
Other (specifically, non-clustered cadherin superfamily protein), Cell adhesion molecule
01

Overview

Cadherin-23 is a type I transmembrane protein belonging to the cadherin superfamily, characterized by a large extracellular domain with 27 cadherin repeats and a cytoplasmic tail. It is a critical component of hair-cell tip links in the inner ear, where it mediates calcium-dependent cell–cell adhesion essential for mechanotransduction—the process by which hair cells convert mechanical sound vibrations into neural signals. The protein is also found in the retina, where it is required for normal photoreceptor cell function. Mutations in the CDH23 gene lead to non-syndromic prelingual hearing loss (DFNB12) and syndromic forms of deafness, particularly Usher syndrome type 1D, a leading cause of inherited deaf-blindness[2][3][4][5].

Other names
KIAA1774KIAA1812UNQ1894/PRO4340CDHR23PITA5USH1Dcadherin-like 23cadherin-related family member 23otocadherinOtocadherin
02

Mechanism of action

Not applicable; CDH23 is not a known direct drug target[5]

03

Biological functions

Cell adhesionMechanotransduction in cochlear hair cellsMaintenance of hair-cell tip link structureSignal transmission in hearing and balancePhotoreceptor cell function in retina[2][4]
04

Disease associations

Hereditary deafness (DFNB12, Usher syndrome type 1D)[2][4]Retinal degeneration (when in context of Usher syndrome)[2][4]
05

Safety considerations

None for direct drug targeting; however, loss-of-function mutations can cause congenital deafness and syndromic hearing loss with vision impairment (Usher syndrome type 1D)[2][4]
06

Interacting drugs

None known; no approved drugs directly target CDH23[5]
07

Biomarkers

Mutations in CDH23 are used as genetic biomarkers for diagnosing forms of hereditary deafness (DFNB12, Usher syndrome type 1D)[4]

Beyond the preview

Go deeper on Cadherin-23 (CDH23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadherin-23 (CDH23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call